NCCN Guidelines for Patients® | Multiple Myeloma - page 56

NCCN Guidelines for Patients
Multiple Myeloma, Version 1.2014
Treatment guide
Active multiple myeloma
Chart 4.4.6
shows the treatment options that
are recommended after an allogeneic stem cell
transplant. An allogeneic transplant is a treatment
in which you receive healthy blood stem cells from
another person. Which treatment is recommended
next depends on how the myeloma responded to
the stem cell transplant. A treatment response is an
outcome or improvement related to treatment. See
page 45 to read about the types of possible treatment
If tests show a treatment response or stable
then you have two treatment options to
choose from. One option is to receive maintenance
treatment as part of a clinical trial. Maintenance
treatment is medicine given in a lower dose or
less frequently to “maintain” good initial treatment
results. (See Chart 4.4.5 on page 52 for a list of
recommended maintenance treatment options.) The
other option is to begin observation—a period of
testing to watch for cancer growth.
If tests show progressive disease,
then you have
two treatment options to choose from. One option
is to receive additional treatment, possibly within a
clinical trial. Additional treatment is given after the first
or previous treatments failed to kill all of the cancer
or keep it away. (See Chart 4.4.3 on page 50 for a list
of recommended options for additional treatment.)
Another option is to receive a donor lymphocyte
infusion. A donor lymphocyte infusion is when you
are given white blood cells from the same person
who donated stem cells for the allogeneic stem cell
Test results
Next treatment
Treatment response or stable disease
Chart 4.4.6 Treatment after allogeneic stem cell transplant
Maintenance treatment on clinical trial, or
Additional treatment on or off clinical trial, or
Donor lymphocyte infusion
Progressive disease
1...,46,47,48,49,50,51,52,53,54,55 57,58,59,60,61,62,63,64,65,66,...82
Powered by FlippingBook